证券日报网讯万孚生物（300482）7月30日在互动平台回答投资者提问时表示，研发投入方面，公司近 年来持续注重研发能力，研发投入均超过营业收入的10%，未来公司仍旧会从守好胶体金荧光基本盘， 开拓化学发光、分子、病理等新技术平台的产品研发。 ...

Core Viewpoint - The company emphasizes the significance of MSI testing for various solid tumor patients, highlighting the current limitations in clinical detection coverage due to the complexity of testing technology and high entry barriers [1] Group 1: Company Technology and Product - The company's product utilizes fluorescent PCR melting curve method, which is characterized by its widespread platform applicability, simplified process, and rapid reporting [1] - The detection time has been reduced from the existing 4-5 hours to 90 minutes, enhancing efficiency [1] - The results interpretation using the melting curve method is more intuitive and convenient compared to existing technologies [1] Group 2: Market and Promotion - The company is currently unable to predict the future market promotion situation for its products, indicating uncertainty in market acceptance and penetration [1]

Core Insights - Guangzhou Wondfo Biotech Co., Ltd. has received approval from the National Medical Products Administration and the Guangdong Provincial Medical Products Administration for nine self-developed test kits [1] - The newly approved thrombus five-item test and tumor marker test kits will provide a richer testing menu and more convenient combinations for clinical use [1] Group 1: Product Development - The thrombus five-item test, including D-Dimer, aids in the auxiliary diagnosis of thrombotic diseases, early diagnosis of DIC, monitoring of thrombolytic and anticoagulant drug efficacy, and diagnosis of vascular endothelial system damage [1] - Wondfo Biotech has launched multiple fully automated chemiluminescence immunoassay analyzers with varying throughput, catering to different application scenarios [1] Group 2: Market Position and Future Plans - The company has obtained over 150 medical device product registrations globally, covering nine major areas including cardiac markers, inflammation, thrombosis, thyroid, sex hormones, anemia, bone metabolism, tumors, and infectious disease testing [1] - Wondfo Biotech aims to continue leveraging its high-level, global R&D innovation system, focusing on technological, product, and service innovations to benefit the public [1]

Company Overview - Wanfu Biology's stock price as of July 29, 2025, is 24.12 yuan, down 0.25 yuan or 1.03% from the previous trading day [1] - The company specializes in the research, development, production, and sales of rapid diagnostic reagents and related instruments, covering areas such as infectious diseases, chronic diseases, and drug testing [1] Market Performance - The opening price on the same day was 24.37 yuan, with a high of 24.38 yuan and a low of 23.68 yuan [1] - The trading volume reached 3.92 billion yuan, with a turnover rate of 3.80% [1] Product Development - Wanfu Biology's wholly-owned subsidiary, Tianshen Medical, recently received approval for 9 self-developed test kits, including thrombosis detection and tumor marker detection reagents [1] - The company has accumulated 16 medical device registration certificates for its single-use chemiluminescence system, covering 9 major areas including cardiac markers, inflammation, and thrombosis [1] Financial Flow - On July 29, the net outflow of main funds was 21 million yuan, accounting for 0.2% of the circulating market value [1]

金融界消息 截至2025年7月29日收盘，万孚生物（300482）报收于24.12元，下跌1.03%，换手率3.8%， 成交量16.36万手，成交金额3.92亿元。 通过天眼查大数据分析，广州万孚生物技术股份有限公司共对外投资了37家企业，参与招投标项目1537 次，知识产权方面有商标信息397条，专利信息729条，此外企业还拥有行政许可1844个。 来源：金融界 万孚生物最新一期业绩显示，截至2025一季报，公司营业总收入8.00亿元、同比减少7.06%，归属净利 润1.89亿元，同比减少13.37%，扣非净利润1.72亿元，同比减少17.57%，流动比率5.781、速动比率 5.298、资产负债率18.69%。 天眼查商业履历信息显示，广州万孚生物技术股份有限公司，成立于1992年，位于广州市，是一家以从 事研究和试验发展为主的企业。企业注册资本47134.2537万人民币，实缴资本29308.7423万人民币。公 司法定代表人为王继华。 资金流向方面，今日主力资金净流出2100.11万元，占比成交额5.35%。其中，超大单净流出574.66万 元、占成交额1.46%，大单净流出1525.44万元、占成交 ...

Group 1 - Wanfu Bio's subsidiary, Tianshen Medical, has recently received approval from the National Medical Products Administration and Guangdong Provincial Medical Products Administration for 9 self-developed test kits, including thrombosis and tumor marker test kits, enhancing clinical testing options [1] - Tianshen Medical specializes in cardiovascular diagnostics and offers a comprehensive range of cardiac marker testing products, including hs-Tnl, cTnl, Myo, CK-MB, BNP, NT-proBNP, D-Dimer, and H-FABP [1] - The newly approved thrombosis five-item test (TAT, PIC, TM, t-PAIC, FDP) is designed for whole blood samples and provides early indicators of changes in the vascular endothelium, coagulation, and fibrinolysis systems, making it suitable for thrombotic risk assessment and early diagnosis [1] Group 2 - The newly approved thrombosis five-item test combined with D-Dimer will aid in the auxiliary diagnosis of thrombotic diseases, early diagnosis of DIC, monitoring of thrombolytic and anticoagulant drug efficacy, and diagnosis of vascular endothelial system damage, offering clinicians more comprehensive and precise diagnostic tools [2] - As of July 2025, Wanfu Bio's single-use chemiluminescence system has obtained 16 medical device registration certificates for tumor marker testing, making it the most comprehensive small-scale luminescence system in China [2] - Wanfu Bio has launched various fully automated chemiluminescence immunoassay analyzers with different throughput for diverse applications, holding over 150 medical device registration certificates globally, covering 9 major testing areas including cardiac markers, inflammation, thrombosis, thyroid, sex hormones, anemia, bone metabolism, tumors, and infectious diseases [2] - The company plans to continue leveraging its high-level, global R&D innovation system, focusing on technological, product, and service innovations [2]

（编辑 姚尧） 证券日报网讯 7月29日晚间，万孚生物发布公告称，公司全资子公司深圳天深医疗器械有限公司近日收 到国家药品监督管理局及广东省药品监督管理局颁发的医疗器械注册证，包括组织型纤溶酶原激活剂- 抑制剂1复合物测定试剂盒（化学发光免疫分析法）等。 ...

Core Viewpoint - Wanfu Biology's subsidiary, Tianshen Medical, has received approval for nine self-developed test kits from the National Medical Products Administration and Guangdong Provincial Drug Administration, enhancing clinical testing options [1] Group 1: Product Development - The approved test kits include thrombosis five-item tests and tumor marker tests, providing a richer testing menu and more convenient combinations for clinical use [1] - By July 2025, Wanfu Biology's single-use chemiluminescence system is expected to have obtained 16 medical device registration certificates for tumor marker detection, making it the most comprehensive small-scale luminescence system in China [1] Group 2: Market Position - Wanfu Biology's single-use chemiluminescence product line has received over 150 medical device registration certificates globally, covering nine major testing areas including cardiac markers, inflammation, thrombosis, thyroid, sex hormones, anemia, bone metabolism, tumors, and infectious diseases [1]

北京商报讯（记者 王寅浩 实习记者 宋雨盈）7月29日，万孚生物发布公告称，公司全资子公司深圳天 深医疗器械有限公司获国家药监局及广东省药监局颁发的9项医疗器械注册证，其中包括血栓五项检测 试剂和肿瘤标志物检测试剂等。 ...

Group 1 - Anhui Construction won a joint bid for the Chongqing Rongchang to Sichuan Zigong expressway project, with a total estimated investment of 3.614 billion yuan and a construction period of 3 years [1] - Hongfa Co. reported a net profit of 964 million yuan for the first half of 2025, a year-on-year increase of 14.19%, with revenue of 8.347 billion yuan, up 15.43% [1][2] - Lujiazui's net profit for the first half of 2025 was 815 million yuan, a decrease of 7.87%, despite a revenue increase of 33.91% to 6.598 billion yuan [3] - Enhua Pharmaceutical achieved a net profit of 700 million yuan, up 11.38%, with revenue of 3.010 billion yuan, an increase of 8.93% [4][5] - China CNR signed several major contracts totaling approximately 32.92 billion yuan, covering various sectors including urban rail vehicles and wind power equipment [6] - WanTong Intelligent signed an exclusive sales and cooperation agreement in the embodied intelligence field, gaining global sales rights for specific chip-based products [7][8] Group 2 - Liansheng Technology's subsidiary received a government subsidy of 13.5 million yuan, accounting for 12.24% of the company's latest audited net profit [9] - Guobang Pharmaceutical reported a net profit of 456 million yuan, a year-on-year increase of 12.60%, with revenue of 3.026 billion yuan, up 4.63% [10] - Baotai expects a net loss of 110 to 140 million yuan for the first half of 2025, a reduction in loss compared to the previous year [11] - Sains expects a net profit decrease of 57.53% to 60.13%, with projected revenue growth of 15.17% to 23.59% [12] - Nanya New Materials anticipates a net profit of 80 to 95 million yuan for the first half of 2025, an increase compared to the previous year [13] - Tian Pharmaceutical's subsidiary passed the consistency evaluation for a peritoneal dialysis solution [14] Group 3 - Shede Liquor announced the resignation of director Ni Qiang due to work reasons [15] - Greentown Water plans to transfer assets and liabilities of its ASEAN subsidiary to improve resource allocation [16] - Beibu Gulf Port's subsidiary signed an associated transaction contract worth 11.199 million yuan [17] - Beibu Gulf Port announced multiple resignations of directors and executives [18] - Jidian Co. reported the resignation of its deputy general manager due to work changes [19] - Wanhua Chemical's industrial park in Fujian resumed production after maintenance [20] Group 4 - Shanghai Pharmaceuticals received approval for a clinical trial of a new indication for its B019 injection [21] - Jianbang Co. reported a net profit of 69.66 million yuan, a decrease of 27.72%, with revenue of 307 million yuan, down 15.37% [23] - Jianbang Co. plans to use up to 400 million yuan of idle funds for cash management [25] - Wanfu Bio's subsidiary obtained multiple medical device registrations [28] - Hunan Tianyan announced a change in its controlling shareholder to China Chang'an Automobile Group [29][30] - Xizhuang Co. plans to establish a joint venture for sustainable aviation fuel [32]